Compare Eli Lilly And Co (LLY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Ultra Short Bond ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard Ultra Short Bond ETF trades at $49.49 (market cap $10.20B). The key difference: Eli Lilly And Co is far larger — about 102× Vanguard Ultra Short Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Ultra Short Bond ETF for 62 Days on average.
| LLY | VUSB | |
|---|---|---|
Market Cap | $1.04T | $10.20B |
Volume | 3,064,878 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $50.03 |
52-Week Low | $799.57 | $49.41 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
VUSB trades at $49.49, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend, while recent news highlights short-term bond ETF appeal amid potential Fed rate hikes. The company has announced upcoming dividends, with three distributions scheduled for H2-2026.
The outlook remains cautious due to bearish technicals and interest rate sensitivity. Opportunities include dividend income, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term stability against macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
